Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
Open Access
- 1 April 1995
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 25 (4), 548-554
- https://doi.org/10.1016/0272-6386(95)90122-1
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The MOS 36-Item Short-Form Health Survey (SF-36)Medical Care, 1993
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- Treatment of the Anemia of Predialysis Patients with Recombinant Human Erythropoietin: A Randomized, Placebo-Controlled TrialThe American Journal of the Medical Sciences, 1988
- The MOS Short-form General Health SurveyMedical Care, 1988
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- Assessing the responsiveness of functional scales to clinical change: An analogy to diagnostic test performanceJournal of Chronic Diseases, 1986
- The Quality of Life of Patients with End-Stage Renal DiseaseNew England Journal of Medicine, 1985
- The CES-D ScaleApplied Psychological Measurement, 1977